HC Wainwright Reiterates “Buy” Rating for Savara (NASDAQ:SVRA)

Savara (NASDAQ:SVRA)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 156.41% from the company’s previous close.

SVRA has been the topic of several other reports. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research report on Monday, September 9th. Oppenheimer boosted their price target on Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, June 26th. Finally, Guggenheim increased their price objective on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $11.17.

Savara Trading Down 2.3 %

NASDAQ SVRA opened at $3.90 on Tuesday. Savara has a one year low of $3.12 and a one year high of $5.70. The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31. The firm has a market cap of $538.94 million, a P/E ratio of -10.54 and a beta of 0.97. The stock’s 50-day moving average is $4.31 and its 200-day moving average is $4.45.

Savara (NASDAQ:SVRA) last posted its earnings results on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). Sell-side analysts anticipate that Savara will post -0.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Savara in the 2nd quarter valued at approximately $215,000. Nantahala Capital Management LLC lifted its stake in Savara by 198.2% in the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after acquiring an additional 3,443,541 shares during the last quarter. Algert Global LLC lifted its stake in Savara by 21.0% in the second quarter. Algert Global LLC now owns 238,807 shares of the company’s stock valued at $962,000 after acquiring an additional 41,377 shares during the last quarter. Frazier Life Sciences Management L.P. increased its stake in shares of Savara by 103.9% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after purchasing an additional 4,157,385 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC raised its holdings in shares of Savara by 46.5% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 115,831 shares of the company’s stock valued at $467,000 after purchasing an additional 36,758 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.